Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00206440 · ClinicalTrials.gov registry record · Phase 3
Nexium Study To Suppress Nausea During Chemotherapy
A Phase 3 study, sponsored by Baylor Breast Care Center.
- Terminated
- Registry status
- Phase 3
- Development phase
- 43
- Enrollment target
NCT00206440 is a Phase 3 study that was terminated before completion, run by Baylor Breast Care Center. The registered enrollment target is 43 participants.
The verdict
NCT00206440, a Phase 3 study, was terminated before completion, sponsored by Baylor Breast Care Center.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 43 participants
- Enrollment target
Study Summary
This study will look at a drug called esomeprazole, the newest PPI, as a way to further reduce the amount of nausea and vomiting seen in breast cancer patients receiving adriamycin or epirubicin chemotherapy. Esomeprazole may help protect the gut lining from the stomach acid and thus lessen the nausea and vomiting. If patients have less stomach sickness, they may be able to enjoy their daily routines much more while they are getting chemotherapy.
Interventions
- OTHER Placebo
- DRUG esomeprazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2005-08 |
| Est. Completion | 2012-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00206440
The ClinicalTrials.gov registry entry for NCT00206440 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baylor Breast Care Center, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00206440 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00206440 about?
NCT00206440 is a clinical study titled "Nexium Study To Suppress Nausea During Chemotherapy". This study will look at a drug called esomeprazole, the newest PPI, as a way to further reduce the amount of nausea and vomiting seen in breast cancer patients receiving adriamycin or epirubicin chemotherapy. Esomeprazole may help protect the gut lining from the stomach acid and thus lessen the naus...
What is the current status of trial NCT00206440?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 43 participants. The study started on 2005-08. Estimated completion is 2012-02.
What interventions are being tested in trial NCT00206440?
The interventions under investigation include: Placebo (OTHER), esomeprazole (DRUG).
Who is sponsoring clinical trial NCT00206440?
This trial is sponsored by Baylor Breast Care Center, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.